FLASCO

 

Corporate Members

Diamond

Platinum

Gold

Silver

Latest News

Dr. Ayman Barakat Joins Florida Cancer Specialists in Hernando County

Posted August 17, 2016

Spring Hill, FL – August 16, 2016. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Ayman Barakat, MD has joined the practice and is seeing patients at two FCS locations in Hernando County, FL. Dr. Barakat will practice at the Brooksville...

BUCCANEERS AND FLORIDA CANCER SPECIALISTS RENEW PARTNERSHIP

Posted August 12, 2016

Tampa, FL – August 10, 2016……… The Tampa Bay Buccaneers and Florida Cancer Specialists & Research Institute (FCS) announced that they have renewed their partnership with a multi-year deal. The work being performed by Florida Cancer Specialists & Research Institute (FCS)in the research and treatment of cancer is making a real difference in the lives...

NCCN Guidelines Updated

Posted August 11, 2016

NCCN has published NEW NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for the following disease type: Testicular Cancer, Version 2.2016 NCCN has published updates to the NCCN Guidelines® and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 1.2017.  Adjuvant...

NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis.

Posted August 8, 2016

NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis. These NCCN Guidelines are currently available as Version 1.2016.  “Clinical Breast Exam” was changed to “Clinical Encounter” with the footnote stating, “Clinical encounter should encompass ongoing risk assessment, risk reduction counseling, as well as a clinical breast exam.” (BSCR-1) “Consider tomosynthesis” is a...

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 1.2016.

Posted August 8, 2016

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 1.2016.   Anaplastic Gliomas (GLIO-2) The following adjuvant treatment option has been removed for 1p19q codeleted anaplastic oligodendroglioma/anaplastic oligoastrocytoma: PCV or temozolomide chemotherapy (category 2B). Glioblastoma...

Who’s Online

There are no users currently online